Zafgen Inc. Appoints Industry Veteran and Recognized Metabolic Disorders Expert Thomas Hughes, Ph.D., as Company’s First Chief Executive Officer
CAMBRIDGE, Mass., September 9, 2008 – Zafgen Inc., a private venture-backed
biopharmaceutical company focused on developing novel obesity therapeutics today announced
that Thomas Hughes, Ph.D., has been named the company’s first chief executive officer. Dr.
Hughes was formerly vice president and global head, cardiovascular and metabolism disease
area, at the Novartis Institutes for BioMedical Research, Inc. in Cambridge, where he directed
drug discovery research teams specializing in cardiovascular disease, type 2 diabetes and related
metabolic disorders.
A rapidly growing epidemic, obesity currently affects an estimated 400 million people
worldwide and drives an expanding prevalence of obesity-related co-morbidities including type 2
diabetes, which is anticipated to affect 380 million people by 2025. Zafgen has developed a
novel approach to treat obesity based on preclinical research around vascular targeting in adipose
tissue. Fat tissue is exceptional for its plasticity, its high degree of vascularization, and its ability
to continuously remodel and grow new blood vessels as it expands. Zafgen’s lead molecules
directly target this ability to remodel and expand, causing the fat tissue to shrink, ultimately
leading to reduction in weight.
“While the currently available treatments for obesity can be effective in the short term, long-term
efficacy has not been consistent with patient and health care provider expectations. Many
existing and emerging agents also have tolerability or safety limitations that reduce their overall
effectiveness or restrict their use,” stated Dr. Hughes. “Vascular targeting of adipose tissue
addresses the fundamental biology of obesity in an entirely new way and may provide a more
effective means to achieve sustainable weight loss. Zafgen’s orally active lead molecules have
demonstrated compelling and durable efficacy and a promising early tolerability profile in
numerous gold-standard obesity models. A unique and powerful peripheral mechanism not only
differentiates these compounds from marketed and investigational obesity therapeutics, but also
is potentially well-suited to combination with existing and emerging therapies impacting weightand
metabolic control. As weight loss, diet, and exercise are the cornerstones of therapy for type
2 diabetes, hypertension, and hypercholesterolemia, well-tolerated agents leading to significant
and sustained weight loss are desperately needed and of potentially great medical value. I believe
Zafgen’s near-term product development opportunities are extraordinarily promising.”
“We are very pleased to appoint a recognized scientific expert and seasoned drug development
executive to lead Zafgen, and Tom’s decision to join our organization is a testament to the
paradigm-shifting approach we are pursuing,” stated Peter Barrett, Ph.D., chairman of Zafgen’s
board of directors and partner, Atlas Venture. “Tom’s experience is ideally suited to lead Zafgen
through our next stage of growth as we prepare to enter the clinic with our first drug candidate in
2009. His move to join Zafgen is further validation of this disruptive approach to treating
obesity.”
During his 20-year tenure at Novartis, Dr. Hughes has been involved in a wide range of drug
discovery efforts in the metabolic and cardiovascular disease area, focusing on glucose
homeostasis, diabetic complications, lipid metabolism, aging biology, and the control of blood
clotting. In addition to serving as head of cardiovascular and metabolism research, Dr. Hughes
also served as the vice president and global head of the diabetes and metabolism disease areas.
From 1995 to 2002, Dr. Hughes was responsible for the conception and leadership of the
dipeptidyl peptidase IV (DPP4) inhibitor program within Novartis research, leading to the
discovery of the marketed antidiabetic compound vildagliptin, for which he was recognized with
the Novartis Distinguished Scientist Award in 2000. Dr. Hughes earned his Ph.D. in nutritional
biochemistry from Tufts University and received an M.S. in Zoology from Virginia Polytechnic
Institute & State University. He graduated with a B.A. in biology from Franklin and Marshall
College.
Kevin Starr, former interim chief executive officer, Zafgen Inc. and partner, Third Rock
Ventures added, "Tom represents a key element in our strategy to grow a truly outstanding
company. In addition to a clear vision, great corporate culture, and first-rate science is –
importantly – leadership. Tom’s leadership is a perfect complement to the exceptional team that
we are assembling at Zafgen. We are at the forefront of a major therapeutic advance in obesity."
Also supporting the company's efforts is a scientific advisory board comprised of several
renowned experts in the fields of obesity and other metabolic disorders, including Lou Tartaglia,
Ph.D., chairman of the Zafgen scientific advisory board, partner, Third Rock Ventures; Maria
Rupnick, M.D., co-founder of Zafgen, instructor in medicine, Children’s Hospital Boston and
acute/critical care cardiologist, Brigham and Women’s Hospital; Randy Seeley, Ph.D., professor,
psychiatry and associate director, the Obesity Research Center, the University of Cincinnati
College of Medicine; Steven Smith, M.D., assistant executive director, clinical research, the
Pennington Biomedical Research Center; and Lou Aronne, M.D., clinical professor of medicine,
Weill Medical College of Cornell University, adjunct clinical associate professor of medicine,
Columbia University and assistant attending physician, New York Presbyterian Hospital.
About Zafgen Inc.
Zafgen Inc. is the first biopharmaceutical company dedicated to developing novel obesity
therapeutics based on vascular targeting in adipose tissue (fat). Zafgen’s groundbreaking
approach directly targets adipose vasculature to shrink fat cells and help the body sustain a lean,
healthy state. Adipose tissue is unique among all tissues in the body for its capacity to expand
and contract based on nutritional and metabolic requirements, and this plasticity is acutely
dependent upon an ability to remodel and grow new blood vessels. Zafgen’s leadership and
scientific advisors include the leading experts in obesity, metabolic disorders and medicinal
chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts. For more
information, visit www.zafgen.com.